Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic…
NCT00002754 · Duke University, Other · Completed
Key facts
| NCT number | NCT00002754 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors |
| Official title | PHASE I STUDY OF MONOCLONAL ANTIBODY FRAGMENT 131I MEL-14 F(AB')2 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT MELANOMA AND OTHER BRAIN TUMORS |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer |
| Intervention type | Biological |
| Interventions | monoclonal antibody Me1-14 F(ab')2 |
| Enrollment | 6 |
| Start date | Feb 1, 1993 |
| Primary completion | Apr 1, 2001 |
| Completion | Apr 1, 2001 |
| First posted | Jul 29, 2004 |
| Last update posted | Feb 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: